Medical devices, healthcare technology and the business of care
PMA approval · P230003

Alinity m HR HPV

Abbott Molecular, Inc. · Decision date Nov 1, 2023

MEDTECHLEDGER EXPLANATIONP230003

What did the FDA approve?

FDA approved PMA P230003 for the Alinity m HR HPV, a qualitative in vitro test that detects Human Papillomavirus DNA in cervical specimens collected by a health care professional using an endocervical brush/spatula placed in ThinPrep PreservCyt Solution or an endocervical broom placed in SurePath Preservative Fluid. The test identifies high-risk HPV types 16, 18, and 45 while reporting concurrent detection of other high-risk genotype groups (31/33/52/58) and (35/39/51/56/59/66/68).

The stated indication covers routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing with cytology, and HPV primary screening to assess risk for cervical pre-cancer and cancer. The statement says patients should be followed up in accordance with professional medical guidelines, prior screening results, medical history, and other risk factors. The record does not include supplement type or reason, so no additional change beyond the original approval scope is described.

FDA approval order statement

Alinity m HR HPV is a qualitative in vitro test for the detection of Human Papillomavirus DNA in cervical specimens collected by a health care professional using an endocervical brush/spatula placed in ThinPrep PreservCyt Solution or an endocervical broom placed in SurePath Preservative Fluid. This test identifies high-risk (HR) HPV types 16, 18, 45, while reporting the concurrent detection of the other HR genotypes (31/33/52/58) and (35/39/51/56/59/66/68).Alinity m HR HPV is indicated for use in routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing(adjunctive screening) with cytology, and HPV primary screening of women to assess the risk for cervical pre-cancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors.
Regulatory pathway
Original PMA
Clinical specialty
Microbiology
Decision date
Nov 1, 2023

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230003
Regulatory pathway
Premarket approval application
Product code
MAQ
Decision code
APPR
Decision date
Nov 1, 2023
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.

Product code
MAQ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P230003 received

    Application receipt date recorded by FDA.

  2. P230003 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P230003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230003

Product / regulatory recordCompanyPathwayDecision dateSource
Alinity m HR HPVP230003/S019
Abbott Molecular, Inc.PMA supplementSep 2, 2026FDA

Explore the linked device profile

Other records with product code MAQ

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HPVP100020/S066
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
cobas HPVP190028/S026
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular Systems, Inc.PMA approvalApr 3, 2020FDA
Roche Molecular Systems, Inc.PMA approvalApr 19, 2011FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Molecular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1300 E Touhy Ave., Des Plaines, IL, 60018

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records